Sunnegårdh Jan
Institute for the Health of Women and Children, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden.
Acta Paediatr. 2006 Apr;95(4):388-90. doi: 10.1080/08035250500544955.
Respiratory syncytial virus (RSV) infection is the leading cause of infection of the lower respiratory tract in infants, and is also the leading cause of hospitalization during the first year of life. In this issue of Acta Paediatrica, Meberg and Bru report on the incidence and estimated costs of hospitalizations for RSV infections in children with congenital heart disease from a specified region in Norway.
Incidence figures of hospitalization due to RSV infection in this high-risk group of infants were similar to the results from several other reports. The cost-benefit analysis of prophylaxis against RSV infection in infants with congenital heart disease, using the monoclonal antibody palivizumab, should also take into account potential savings attributable to such prophylaxis.
呼吸道合胞病毒（RSV）感染是婴儿下呼吸道感染的主要原因，也是一岁内住院的主要原因。在本期《儿科学报》中，梅伯格和布鲁报告了挪威特定地区先天性心脏病患儿RSV感染住院的发病率及估计费用。
这一高危婴儿群体中因RSV感染住院的发病率数据与其他几份报告的结果相似。使用单克隆抗体帕利珠单抗对先天性心脏病婴儿预防RSV感染的成本效益分析，也应考虑到这种预防措施可能带来的节省。
